zanamivir has been researched along with cs 8958 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kakuta, M; Kubo, S; Nasu, H; Tokumitsu, A; Tomozawa, T; Yamashita, M | 1 |
| Arai, M; Honda, T; Kobayashi, Y; Kubo, S; Masuda, T; Yamashita, M | 1 |
| Kakuta, M; Kubo, S; Tokumitsu, A; Tomozawa, T; Yamashita, M | 1 |
| Koyama, K; Miura, S; Nakai, N; Oitate, M; Okazaki, O; Takahashi, M; Takakusa, H | 1 |
| Ishizuka, H; Okabe, H; Yoshiba, S; Yoshihara, K | 2 |
| Hoshi, M; Kobayashi, N; Koyama, K; Murai, T; Nakai, N; Okazaki, O; Takahashi, M; Takakusa, H; Yamamura, N | 1 |
| Kawaoka, Y; Kiso, M; Kubo, S; Le, QM; Nidom, CA; Ozawa, M; Yamashita, M | 1 |
| Ohashi, Y; Sugaya, N | 1 |
| Yamashita, M | 1 |
| Kakuta, M; Kubo, S; Yamashita, M | 1 |
| Li, MS; Mai, BK | 1 |
| Li, Y; Ma, D; Tian, J; Zhong, J | 1 |
1 review(s) available for zanamivir and cs 8958
| Article | Year |
|---|---|
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Guanidines; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pandemics; Prodrugs; Pyrans; Rats; Sialic Acids; Zanamivir | 2010 |
3 trial(s) available for zanamivir and cs 8958
| Article | Year |
|---|---|
Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
Topics: Administration, Inhalation; Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Half-Life; Humans; Male; Middle Aged; Neuraminidase; Prodrugs; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2010 |
Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Area Under Curve; Enzyme Inhibitors; Female; Guanidines; Half-Life; Humans; Male; Middle Aged; Neuraminidase; Prodrugs; Pyrans; Renal Insufficiency; Severity of Illness Index; Sialic Acids; Zanamivir | 2011 |
Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Virus Shedding; Zanamivir | 2010 |
9 other study(ies) available for zanamivir and cs 8958
| Article | Year |
|---|---|
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; HeLa Cells; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Neuraminidase; Prodrugs; Zanamivir | 2009 |
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
Topics: Administration, Intranasal; Alphainfluenzavirus; Animals; Antiviral Agents; Betainfluenzavirus; Esters; Mice; Neuraminidase; Prodrugs; Zanamivir | 2009 |
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Treatment Outcome; Zanamivir | 2010 |
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
Topics: Animals; Antiviral Agents; Autoradiography; Enzyme Inhibitors; Esterases; Female; Guanidines; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Prodrugs; Pyrans; Sialic Acids; Trachea; Zanamivir | 2009 |
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
Topics: Animals; Antiviral Agents; Bile; Chromatography, Thin Layer; Enzyme Inhibitors; Feces; Guanidines; Male; Neuraminidase; Prodrugs; Pyrans; Radioactivity; Rats; Rats, Sprague-Dawley; Sialic Acids; Time Factors; Tissue Distribution; Tissue Extracts; Zanamivir | 2010 |
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Topics: Animals; Antiviral Agents; Female; Guanidines; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 2010 |
[In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cells, Cultured; Delayed-Action Preparations; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Pandemics; Viral Load; Virus Replication; Zanamivir | 2010 |
Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Topics: Antiviral Agents; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Molecular Dynamics Simulation; Mutation; Neuraminidase; Pyrans; Sialic Acids; Zanamivir | 2011 |
Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958.
Topics: Antiviral Agents; Catalysis; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir | 2014 |